AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26965168 — intervention group
Group type: COMPARATOR
Intervention: Non-elective admission (90 patients)
Number of subjects: 178
Study 26965168 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective admission
Number of subjects: 178
Study 26965168 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with APACHE IV score
Number of subjects: 178
Study 26965168 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of infection
Number of subjects: 178
Study 26965168 — intervention group
Group type: COMPARATOR
Intervention: Type of admission
Number of subjects: 178
Study 26965288 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-lipid panel in BALF
Number of subjects: 114
Study 26965288 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent cohort replication
Number of subjects: 114
Study 26965288 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotoxin levels
Number of subjects: 114
Study 26965296 — intervention group
Group type: EXPERIMENTAL
Intervention: FG-3019 administered by intravenous infusion every 3 weeks for 45 weeks
Number of subjects: 0
Study 26965296 — intervention group
Group type: EXPERIMENTAL
Intervention: FG-3019
Number of subjects: 0
Study 26965536 — intervention group
Group type: EXPERIMENTAL
Intervention: High CFR with low IMR (Group A)
Number of subjects: 313
Study 26965536 — intervention group
Group type: EXPERIMENTAL
Intervention: High CFR with high IMR (Group B)
Number of subjects: 313
Study 26965536 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CFR with low IMR (Group C)
Number of subjects: 313
Study 26965536 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CFR with high IMR (Group D)
Number of subjects: 313
Study 26965536 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CFR
Number of subjects: 313
Study 26965536 — intervention group
Group type: EXPERIMENTAL
Intervention: High IMR with low CFR
Number of subjects: 313
Study 26965536 — intervention group
Group type: EXPERIMENTAL
Intervention: Overt microvascular disease
Number of subjects: 313
Study 26965536 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel disease
Number of subjects: 313
Study 26965536 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 313
Study 26965536 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological index inclusion
Number of subjects: 313
Study 26965794 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical treatment with commonly used antimicrobials as per IDSA guidelines
Number of subjects: 447
Study 26965794 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 447
Study 26965870 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridisation (FISH)
Number of subjects: 120
Study 26965870 — intervention group
Group type: EXPERIMENTAL
Intervention: Nugent scoring
Number of subjects: 120
Study 26965915 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin 14 mg/m² on days 1, 8, and 15 of six 28-day cycles; maintenance dosing twice per cycle after 12 cycles, and potentially reduced to once per cycle after 24 cycles for those who had received maintenance for ≥6 months.
Number of subjects: 130
Study 26965915 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin (continuation of treatment for patients with SD),
Number of subjects: 130
Study 26966027 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3026 (oral ALK inhibitor) at doses of 25-800 mg once daily in 28-day cycles
Number of subjects: 46
Study 26966027 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3026 (oral ALK inhibitor)
Number of subjects: 46
Study 26966029 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Lemtrada®)
Number of subjects: 15
Study 26966545 — intervention group
Group type: EXPERIMENTAL
Intervention: e-therapeutic platform (Next.Step) used for 12 weeks in addition to standard intervention
Number of subjects: 80
Study 26966545 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 80
Study 26966551 — intervention group
Group type: EXPERIMENTAL
Intervention: CAU plus IBD-specific cognitive-behavioural therapy (CBT)
Number of subjects: 100
Study 26966551 — intervention group
Group type: COMPARATOR
Intervention: Medical care-as-usual (CAU)
Number of subjects: 100
Study 26966573 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusions (RBCTx)
Number of subjects: 1018
Study 26966573 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 1018
Study 26966573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) iron
Number of subjects: 1018
Study 26966573 — intervention group
Group type: EXPERIMENTAL
Intervention: ESA + IV iron
Number of subjects: 1018
Study 26966573 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall antianemic therapy
Number of subjects: 1018
Study 26967692 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete nephrogenic DI
Number of subjects: 41
Study 26967692 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary polydipsia (PP)
Number of subjects: 41
Study 26967692 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete central DI
Number of subjects: 41
Study 26967692 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 41
Study 26967774 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized analgesia protocol
Number of subjects: 96
Study 26968374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and laboratory parameters assessed daily for up to 6 days during acute illness and at a follow-up visit 1 week later.
Number of subjects: 8000
Study 26968374 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with confirmed dengue.
Number of subjects: 8000
Study 26968374 — intervention group
Group type: EXPERIMENTAL
Intervention: Early virological and serological correlates of severe disease.
Number of subjects: 8000
Study 26968374 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of the new World Health Organization classification scheme for dengue.
Number of subjects: 8000
Study 26968534 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib and entospletinib combination therapy
Number of subjects: 0
Study 26968708 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-targeted CAR-T cell infusions
Number of subjects: 11
Study 26968833 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal arterial ischemic stroke (NAIS)
Number of subjects: 80
Study 26969082 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation (with or without prior central nervous system irradiation)
Number of subjects: 588
Study 26969082 — intervention group
Group type: COMPARATOR
Intervention: Transplanted patients who never received any irradiation
Number of subjects: 588
Study 26969082 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplanted without total body irradiation who received central nervous system irradiation
Number of subjects: 588
Study 26969082 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients irradiated or transplanted at older than 10 years of age
Number of subjects: 588
Study 26969082 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid malignancy
Number of subjects: 588
Study 26969258 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole 200 mg three times daily for six doses, followed by 200 mg/day until resolution, failure, or for 180 days; median treatment duration was 84 days (IQR 19-179, range 2-882).
Number of subjects: 37
Study 26969258 — intervention group
Group type: COMPARATOR
Intervention: Isavuconazole (primary treatment)
Number of subjects: 37
Study 26969509 — intervention group
Group type: EXPERIMENTAL
Intervention: Flemish CARES tool
Number of subjects: 150
Study 26969509 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial patient survey
Number of subjects: 150
Study 26969509 — intervention group
Group type: EXPERIMENTAL
Intervention: Second survey after 1 week
Number of subjects: 150
Study 26970381 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCy, tacrolimus, and MMF
Number of subjects: 86
Study 26970381 — intervention group
Group type: COMPARATOR
Intervention: ATG, tacrolimus, and methotrexate or MMF
Number of subjects: 86
Study 26970832 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relaxin-2 levels soon after delivery
Number of subjects: 98
Study 26970832 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sFlt1 levels
Number of subjects: 98
Study 26970970 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 45
Study 26970970 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 45
Study 26971081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/day
Number of subjects: 172
Study 26971081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg/day
Number of subjects: 172
Study 26971081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 300 mg/day
Number of subjects: 172
Study 26971081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 400 mg/day
Number of subjects: 172
Study 26971081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (any dose)
Number of subjects: 172
Study 26971081 — intervention group
Group type: COMPARATOR
Intervention: Sertraline 100-200 mg/day
Number of subjects: 172
Study 26971192 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug taper
Number of subjects: 540
Study 26971192 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering to no medications
Number of subjects: 540
Study 26971192 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials requiring treatment resistance
Number of subjects: 540
Study 26971192 — intervention group
Group type: EXPERIMENTAL
Intervention: History of suicidal ideation or behaviour
Number of subjects: 540
Study 26971192 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall research participation
Number of subjects: 540
Study 26971488 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG background pattern at 24h
Number of subjects: 0
Study 26971488 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG background pattern within 12h
Number of subjects: 0
Study 26971488 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive values of EEG
Number of subjects: 0
Study 26971488 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactivity parameters
Number of subjects: 0
Study 26971488 — intervention group
Group type: COMPARATOR
Intervention: Treatment of electrographic status epilepticus
Number of subjects: 0
Study 26971680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal injection of autologous bone marrow-derived mesenchymal stromal cells (MSCs) at a median dose of 1.2 × 10(6) MSCs/kg body weight, with 2-3 injections per patient.
Number of subjects: 9
Study 26971692 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 therapy
Number of subjects: 0
Study 26972567 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived endothelial progenitor cells (EPC), administered through the hepatic artery in a single administration.
Number of subjects: 12
Study 26973142 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels at admittance
Number of subjects: 124
Study 26973142 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment after 6 weeks
Number of subjects: 124
Study 26973142 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline CRP levels
Number of subjects: 124
Study 26973324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg/day
Number of subjects: 246
Study 26973445 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive and physical intervention scheme (LLM)
Number of subjects: 50
Study 26973445 — intervention group
Group type: COMPARATOR
Intervention: Active control group (AC)
Number of subjects: 50
Study 26973538 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole exome sequencing to identify genetic mutations.
Number of subjects: 0
Study 26973791 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dextran (Infufer®)
Number of subjects: 143
Study 26973791 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (Venofer®)
Number of subjects: 143
Study 26973849 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (Perenterol forte 250 mg capsules, twice per day for 7 days after antibiotic discontinuation)
Number of subjects: 477
Study 26973849 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo, twice per day for 7 days after antibiotic discontinuation)
Number of subjects: 477
Study 26973849 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 477
Study 26973849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 26974332 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD quadrants C+D
Number of subjects: 136
Study 26974332 — intervention group
Group type: EXPERIMENTAL
Intervention: mMRC score ≥2
Number of subjects: 136
Study 26974332 — intervention group
Group type: COMPARATOR
Intervention: mMRC, CAT, CCQ questionnaires
Number of subjects: 136
Study 26974430 — intervention group
Group type: EXPERIMENTAL
Intervention: Group drumming intervention for 10 weeks
Number of subjects: 0
Study 26974430 — intervention group
Group type: COMPARATOR
Intervention: Non-music control group
Number of subjects: 0
Study 26974526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg q24h
Number of subjects: 30
Study 26974526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg q12h
Number of subjects: 30
Study 26974526 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone (Period 1)
Number of subjects: 30
Study 26974547 — intervention group
Group type: COMPARATOR
Intervention: Physical activity levels (measured by daily step counts using accelerometry)
Number of subjects: 30
Study 26974547 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity levels in ICU survivors with preexisting chronic disease
Number of subjects: 30
Study 26974547 — intervention group
Group type: COMPARATOR
Intervention: Health-related quality of life (measured by the 36-item short-form health survey)
Number of subjects: 30
Study 26974547 — intervention group
Group type: COMPARATOR
Intervention: Frailty (measured by Clinical Frailty Score)
Number of subjects: 30
Study 26975189 — intervention group
Group type: EXPERIMENTAL
Intervention: dHER2 immunotherapeutic
Number of subjects: 40
Study 26975937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mixed-meal tolerance test (OMTT)
Number of subjects: 240
Study 26976424 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg intravenously once per week
Number of subjects: 37
Study 26976424 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 75 mg intravenously once per week
Number of subjects: 37
Study 26976424 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg and 75 mg cohorts
Number of subjects: 37
Study 26976799 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir for 12 weeks (with ribavirin for genotype 1a patients)
Number of subjects: 20
Study 26976799 — intervention group
Group type: EXPERIMENTAL
Intervention: ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir for 12 weeks (without ribavirin for genotype 1b patients)
Number of subjects: 20
Study 26976799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin therapy
Number of subjects: 20
Study 26976799 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 20
Study 26976872 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 94
Study 26976872 — intervention group
Group type: COMPARATOR
Intervention: Echinocandins/L-AmB-based regimen
Number of subjects: 94
Study 26976960 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical safety checklists implemented in pediatric surgery
Number of subjects: 28772
Study 26976960 — intervention group
Group type: COMPARATOR
Intervention: Pre-checklist group
Number of subjects: 28772
Study 26976960 — intervention group
Group type: COMPARATOR
Intervention: Post-checklist group
Number of subjects: 28772
Study 26977746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside-Sparing Regimens with Raltegravir and a Boosted Protease Inhibitor
Number of subjects: 0
Study 26977746 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26978384 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal blood lead level (BLL) > 50 µg/L
Number of subjects: 910
Study 26978384 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's blood lead level (BLL) > 50 µg/L
Number of subjects: 910
Study 26978384 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BLL associated with offspring's consumption of piped water and animals killed by ammunition
Number of subjects: 910
Study 26978384 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's BLL associated with presence of paint chips in the house and consumption of animals killed by ammunition
Number of subjects: 910
Study 26978384 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's BLL highly associated with maternal BLL on multivariate analyses
Number of subjects: 910
Study 26978775 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable intranasal mucosal atomization device (DIMAD)
Number of subjects: 252
Study 26978775 — intervention group
Group type: COMPARATOR
Intervention: Standard reusable nasal atomizer (CRNA)
Number of subjects: 252
Study 26978775 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' satisfaction with DIMAD
Number of subjects: 252
Study 26979084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense exercise
Number of subjects: 0
Study 26979084 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26980207 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessments using a standardized battery of functional brain imaging, structural brain imaging, and behavioral probes.
Number of subjects: 0
Study 26980207 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 3 months after baseline.
Number of subjects: 0
Study 26980473 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib (250 mg, three times daily)
Number of subjects: 54
Study 26980480 — intervention group
Group type: EXPERIMENTAL
Intervention: PepCan 50 μg
Number of subjects: 31
Study 26980480 — intervention group
Group type: EXPERIMENTAL
Intervention: PepCan 100 μg
Number of subjects: 31
Study 26980480 — intervention group
Group type: EXPERIMENTAL
Intervention: PepCan overall
Number of subjects: 31
Study 26980480 — intervention group
Group type: EXPERIMENTAL
Intervention: PepCan
Number of subjects: 31
Study 26981247 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCOS-102 plus daily low-dose oral cyclophosphamide (CPO)
Number of subjects: 12
Study 26981247 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCOS-102
Number of subjects: 12
Study 26981283 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted home exercise program
Number of subjects: 57
Study 26981283 — intervention group
Group type: COMPARATOR
Intervention: Printed instructions for home exercises
Number of subjects: 57
Study 26982008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 293
Study 26982008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 293
Study 26982511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib therapy
Number of subjects: 66
Study 26983018 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch
Number of subjects: 0
Study 26983018 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 0
Study 26983912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib plus CapeOx (capecitabine and oxaliplatin)
Number of subjects: 66
Study 26984361 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1450
Study 26984361 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1450
Study 26984361 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1450
Study 26984445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (10 mg/kg) administered intravenously every 21 days for 3 cycles
Number of subjects: 66
Study 26984445 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg orally) as a positive control
Number of subjects: 66
Study 26984642 — intervention group
Group type: EXPERIMENTAL
Intervention: cobas KRAS mutation test
Number of subjects: 461
Study 26984642 — intervention group
Group type: COMPARATOR
Intervention: therascreen KRAS RGQ PCR kit test
Number of subjects: 461
Study 26985232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum bv. infantis CCUG 52,486 combined with gluco-oligosaccharide (B. longum + Gl-OS)
Number of subjects: 0
Study 26985232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26986777 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective block of the four principal nerves in the arm
Number of subjects: 0
Study 26986777 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26987488 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban administered within 30 days of the index stroke for secondary prevention of stroke
Number of subjects: 2000
Study 26987662 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared control using BMI and robotic assistance
Number of subjects: 2
Study 26987662 — intervention group
Group type: COMPARATOR
Intervention: BMI control alone
Number of subjects: 2
Study 26987662 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared control
Number of subjects: 2
Study 26988350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulance presentation
Number of subjects: 1068
Study 26988379 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged VF detection (30/40 intervals)
Number of subjects: 705
Study 26988379 — intervention group
Group type: COMPARATOR
Intervention: Standard VF detection (18/24 intervals)
Number of subjects: 705
Study 26989059 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega loop gastric bypass
Number of subjects: 46
Study 26989103 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients with ACOS
Number of subjects: 0
Study 26989103 — intervention group
Group type: COMPARATOR
Intervention: COPD patients without ACOS
Number of subjects: 0
Study 26990515 — intervention group
Group type: EXPERIMENTAL
Intervention: Linox ICD leads
Number of subjects: 3840